Ask the Expert: Targeted Therapies for Gliomas

What is targeted therapy for gliomas in children and adults?

Gliomas can be either low grade (LGG) or high grade (HGG) including anaplastic oligodendroglioma, anaplastic astrocytoma and glioblastoma multiforme.

Significant improvements have been made for initial therapy of HGG, especially in adults with combined chemoradiation using low dose temozolomide followed by temozolomide chemotherapy. However, HGG usually recur or progress after this combined treatment approach. There are many explanations for this, including cancer cell resistance to chemotherapy and abnormal cancer cell signalling, often due to gene mutations of components in these pathways.

Therapies that target specific proteins are known as targeted therapies. Recent studies of HGG have identified key growth factors and their receptors, including the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Targeted therapies use antibodies or small molecule inhibitors to block growth factors or their receptors, blocking glioma cell communication, growth and division.

Some targeted therapies have shown promise in patients with recurrent disease and are being studied in newly diagnosed HGG patients by adding them to standard treatment. However, the effectiveness of targeted therapies usually decreases over time since HGG are able to find ways to grow and invade normal brain despite specific treatment.

There is no established use for targeted therapies in LGG in children or adults outside of a clinical trial. However, there are special indications in LGG patients with inherited disorders such as Neurofibromatosis Type I (NFI) or Tuberous Sclerosis with subependymal giant cell astrocytoma (SEGA).

Patients with HGG are being entered on clinical trials to determine the best way to use these new drugs, including how to combine them with chemotherapy and identify which individual patients can benefit from their use. To date, most of these targeted therapies have shown less promise in children when compared to adults, suggesting that most pediatric HGG have a different biology than adult HGG.
 

You can download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf).
Thank you to Dr David Eisenstat, MD, MA, FRCPC Director of Neuro-Oncology: Adult and Pediatric; CancerCare Manitoba,; Winnipeg, MB. Dr. Eisenstat is a member of the Profressional Advisory Group for Brain Tumour Foundation of Canada.

Return to Information Sheets here.

Share This

Featured Story

Grey Matters - Blogger Tuesdays

Have you seen our blog lately? Read about people who are making a difference in the brain tumour community from our staff and volunteers to our donors, funded researchers, and medical experts. You will find advice, news, information, and interesting stories about people affected by a brain tumour. Who doesn't love a good story? You won't want to miss the inside scoop Grey Matters has in store for you!

Learn more

Spotlight

Roy and the Gamma Knife – A Happy Tale

I had headaches, almost daily, for 10 years or more. It was a rare day if I did not have a headache. I used to joke that I should own...

Learn more

Courtney’s Story of Stability

Stability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour...

Learn more

Upcoming Events

  • 20/Apr/2018: Caregiver Wellness Day: Royal Oaks Golf Club, Moncton, NB... Learn more >
  • 25/Apr/2018: Toronto Support Group: Meets at Wellspring Westerkirk House at Sunnybrook, Toronto, ON... Learn more >
  • 25/Apr/2018: Ottawa Support Group: Meets at the Maplesoft Centre at 1500 Alta Vista Drive, Ottawa, ON.... Learn more >
  • 26/Apr/2018: Brain Fair: BMO Centre, 295 Rectory St, London, ON... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001